Tislelizumab Lenvatinib
Showing 1 - 25 of 636
Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- Tislelizumab
- Tislelizumab, Lenvatinib
- (no location specified)
Mar 29, 2023
Hepatocellular Carcinoma, Lenvatinib, Tislelizumab Trial in Hangzhou (TACE, Tislelizumab, Lenvatinib)
Not yet recruiting
- Hepatocellular Carcinoma
- +5 more
- TACE
- Tislelizumab, Lenvatinib
-
Hangzhou, Zhejiang, China1# Banshan East Rd. Zhejiang cancer hospital
Jun 17, 2023
Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer Trial in Tianjin
Recruiting
- Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Nov 16, 2022
Advanced Kidney Cancer Trial in Tianjin (Tislelizumab Lenvatinib)
Recruiting
- Advanced Kidney Cancer
- Tislelizumab Lenvatinib
-
Tianjin, Tianjin, ChinaChangyi Quan
Aug 4, 2022
Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)
Recruiting
- Solid Tumor, Adult
- Tislelizumab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Sep 13, 2023
Fumarate Hydratase Deficient Renal Cell Carcinoma Trial (Tislelizumab, Lenvatinib)
Not yet recruiting
- Fumarate Hydratase Deficient Renal Cell Carcinoma
- Tislelizumab
- Lenvatinib
- (no location specified)
May 18, 2023
Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC)
Recruiting
- Hepatocellular Carcinoma
- Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Jul 12, 2023
Hepatocellular Carcinoma Trial in Beijing (Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE))
Recruiting
- Hepatocellular Carcinoma
- Lenvatinib Plus Tislelizumab
- Transarterial Chemoembolization(TACE)
-
Beijing, Beijing, ChinaNan Zhang
Apr 22, 2023
Hepatocellular Carcinoma Trial (Cryoablation, Tislelizumab, Lenvatinib)
Not yet recruiting
- Hepatocellular Carcinoma
- Cryoablation
- +2 more
- (no location specified)
May 31, 2023
Gastric Cancer Metastatic to Liver Trial in Shanghai (Cryoablation, Tislelizumab, Lenvatinib)
Not yet recruiting
- Gastric Cancer Metastatic to Liver
- Cryoablation
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 6, 2023
Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)
Recruiting
- Unresectable Hepatocellular Carcinoma
- D-TACE
- +3 more
-
Nanchang, Jiangxi, ChinaThe Second Affiliated Hospital of Nanchang University
Oct 14, 2022
Hepatocellular Carcinoma Trial (Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle)
Not yet recruiting
- Hepatocellular Carcinoma
- Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
- (no location specified)
Jun 12, 2023
Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,
Not yet recruiting
- Hepatocellular Carcinoma
- +2 more
- Adjuvant tislelizumab plus lenvatinib
- Adjuvant tislelizumab
-
Nanning, ChinaJian-Hong Zhong
Jun 11, 2023
Melanoma Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)
Recruiting
- Melanoma
- Tislelizumab
- +2 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 8, 2022
Hepatocellular Carcinoma Resectable Trial in Fuzhou (neoadjuvant therapy)
Not yet recruiting
- Hepatocellular Carcinoma Resectable
- neoadjuvant therapy
-
Fuzhou, Fujian, ChinaThe First Affiliated Hospital of Fujian Medical University
Aug 19, 2023
Tislelizumab, Lenvatinib, TACE Trial in Nanning (Tislelizumab and Lenvatinib)
Active, not recruiting
- Tislelizumab
- +3 more
- Tislelizumab and Lenvatinib
-
Nanning, Guangxi, ChinaThe Affiliated Cancer Hospital of Guangxi Medical University
Jan 25, 2023
Advanced Hepatocellular Carcinoma Trial in Shanghai (Tislelizumab, lenvatinib, US/CT-guided Percutaneous Cryoablation)
Recruiting
- Advanced Hepatocellular Carcinoma
- Tislelizumab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 8, 2022
Biliary Tract Cancer, PD-1 Antibody, Gemox Trial in Shanghai (PD-1+Lenvatinib+GEMOX)
Recruiting
- Biliary Tract Cancer
- +3 more
-
Shanghai, ChinaZhongshan hospital
Dec 11, 2021
Advanced Cholangiocarcinoma Trial in Hangzhou (Lenvatinib, tislelizumab, gemcitabine and cisplatin, Gemcitabine and cisplatin)
Not yet recruiting
- Advanced Cholangiocarcinoma
- Lenvatinib, tislelizumab, gemcitabine and cisplatin
- Gemcitabine and cisplatin
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital, Zhejiang University School of Me
Apr 10, 2023
Biliary Tract Cancer Trial in Shanghai (Capecitabine combined with lenvatinib and tislelizumab)
Recruiting
- Biliary Tract Cancer
- Capecitabine combined with lenvatinib and tislelizumab
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 23, 2022
Potentially Resectable Locally Advanced Malignant Tumors of Biliary System Trial (Tislelizumab)
Not yet recruiting
- Potentially Resectable Locally Advanced Malignant Tumors of Biliary System
- (no location specified)
Sep 6, 2021
Recurrent Hepatocellular Carcinoma Trial in Guangzhou (Tislelizumab, Tislelizumab combined with Levatinib)
Recruiting
- Recurrent Hepatocellular Carcinoma
- Tislelizumab
- Tislelizumab combined with Levatinib
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Mar 31, 2022
Hepatocellular Carcinoma Trial in Wuhan (Nocardia rubra cell wall skeleton, Hepatic arterial infusion chemo, Lenvatinib)
Recruiting
- Hepatocellular Carcinoma
- Nocardia rubra cell wall skeleton
- +3 more
-
Wuhan, Hubei, ChinaHepatic Surgery Center, Tongji Hospital, Tongji Medical College,
Sep 5, 2022